Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Biotechnology and life science company AgenoLab is growing skin cells for transplantation
Improved quality of life for patients with chronic wounds

(Stuttgart) ­ Since its foundation three years ago, AgenoLab GmbH & Co. KG in Stuttgart has become a leading service provider in the area of life sciences and biotechnology. The company's cell culture technology unit focuses on the preparation of cells that can largely eliminate the need for animal testing. In the area of regenerative medicine, AgenoLab GmbH concentrates on the growth of skin cells as transplants for patients suffering from burns and chronic wounds. The development of further cell therapeutics is another area of interest. The company has recently launched an innovative full-thickness skin transplant for healing wounds using the patient's own cells. Within the framework of the Users¹ Centre for Regenerative Medicine in the Neckar-Alb and Stuttgart health region (REGiNA), which is currently in the process of being established, AgenoLab is being supported by the German Federal Ministry of Education and Research (BMBF) with just short of Euro 1 million for two projects, one of which is the development of the above-mentioned full-thickness skin transplant.

Cosmetics, ointments, chemicals, detergents and medical products all have to undergo skin tolerance tests before they can be launched on the market. The life science and biotechnology company AgenoLab GmbH & Co. KG, founded in 2007, is equipped with a GMP laboratory covering 600 square metres, where scientists are developing three-dimensional skin models for test purposes. The GMP quality standard, based on state-of-the-art technology and highly trained staff, ensures optimum safety and highest product quality. The human cell associations grown in the laboratory consist of the subcutis and a multi-layer epidermis with a horned layer (stratum corneum). These cell groups can eliminate the need for animal testing. Human skin, for example left over from operations, is used to build the requisite skin model. Skin cells in the tissue are isolated from either the epidermis or subcutis. Both variants are equally suitable for cosmetic, pharmacological, immunological and molecular biology trials. ³We are the first biotechnology company in Germany to use the xCELLigence cell assay system to conduct label-free real time monitoring of cells and perform online measurements of their biological effectiveness. The latest generation of equipment even makes it possible to measure the migration properties of cells,² explains Dr. Andreas Emmendörffer, Research Director at AgenoLab. ³This innovative cell culture technology is supported by cutting-edge molecular analysis methods for determining the risks posed by substances, raw materials and ingredients, for example. This makes it possible to reduce the number of animal experiments, which gives rise to many benefits over and above the ethical implications.² For instance, in vitro cell tests can be used to verify the tolerance of cosmetics, pharmaceuticals, chemicals and medical products in line with the EU chemical regulation REACH.

Furthermore, at the end of 2008, the young company unveiled a licensed technology for the production of autologous skin transplants grown from patients' own skin, known as KeraSeed. Using this technology, skin cells from biopsies are supplied in a fibrin adhesive (physiological two-component adhesive of biological origin) for transplantation. This procedure is used, for example, to treat burns victims, patients requiring plastic surgery and for the treatment of chronic wounds. ³Three million people in Germany suffer from chronic wounds that often do not heal despite targeted and systematic local treatment. Our skin transplant can help close the wounds and thus ease the pain,² says Dr. Emmendörffer, adding that data from a multicentric study (phase IIb/III) were published for this product in 2007. ³Additionally, AgenoLab has the technology required to grow autologous melanocytes to treat vitiligo, which causes depigmentation of the skin.² In this case, the patient's own healthy pigment cells are extracted from a small skin sample with normal pigmentation. These are then grown in cell culture dishes before they are transplanted in the affected ³white² areas, where they produce melanin to create normal pigmentation.

Within the framework of the Users¹ Centre for Regenerative Medicine in the Neckar-Alb and Stuttgart health region (REGiNA), which is currently being established, AgenoLab is being supported by the BMBF with Euro 900,000 for two projects, one of which is the development of a full-thickness skin transplant. ³In the area of skin and wound treatment, we expect new products, such as those from AgenoLab, to deliver significantly improved healing results,² confirms Dr. Klaus Eichenberg, Managing Director of BioRegio STERN Management GmbH. ³It is now important to ensure that innovative procedures such as these are made available through the state healthcare system.²

About BioRegio STERN:
BioRegio STERN Management GmbH is a skill-sharing network, providing a help and advice centre for founders of new businesses, entrepreneurs and researchers in the biotechnology sector in the region comprising Stuttgart, Tübingen, Esslingen, Reutlingen and Neckar-Alb in Germany. BioRegio STERN promotes cooperation between such different disciplines as medicine, biochemical engineering, sensor technology, dietetics, biochemical analysis and bioinformatics. Key areas of focus are regenerative medicine and medical technology. BioRegio STERN represents the interests of founders of new businesses, entrepreneurs and researchers when dealing with the political sector, the media and associations, coordinates economic promotional activities and marketing and provides advice for grant applications and corporate financing, all backed up with efficient press and public relations work. BioRegio STERN is supported by the Stuttgart and Neckar-Alb regional authorities and the municipal authorities of Stuttgart, Tübingen, Esslingen and Reutlingen. The Managing Director, Dr. Klaus Eichenberg, is a molecular and cell biologist and investment analyst.

About AgenoLab:
AgenoLab GmbH & Co. KG is an innovative biotechnology and life science company that was founded in 2007 in Stuttgart-Wangen. The company focuses primarily on microbiological research for SMEs in the pharmaceutical industry. In the area of regenerative wound treatment, AgenoLab's main area of interest is the preparation of cells as transplants for burns patients and patients with chronic wounds. Within the framework of the Users¹ Centre for Regenerative Medicine in the Neckar-Alb and Stuttgart health region (REGiNA), which is currently being established, AgenoLab is being supported by the BMBF with just short of Euro 1 million for two projects, one of which is the development of a full-thickness skin graft. AgenoLab has a workforce of ten employees. Dr. Andreas Greither is the owner and Managing Director and Dr. Andreas Emmendörffer is Research Director.

Publisher: BioRegio STERN Management GmbH, Friedrichstrasse 10, 70174
Stuttgart, Germany, +49-711-8703540,,
Editor: Zeeb Kommunikation, Hohenheimer Strasse 58a, 70184 Stuttgart,
Germany, +49-711-6070719,,
AgenoLab GmbH & Co. KG: Dr. Andreas Emmendörffer, (Research Director),
Kesselstrasse 17, 70327 Stuttgart, Germany, +49-711-3513842,,

Publisher Contact Information:


Company profile of BioRegio STERN Management
Past press releases of BioRegio STERN Management.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Jan 10€20.0MBusiness applications
Jan 10€20.0MBiotechnology
Jan 10€13.5MArtificial Intelligence
Jan 9€4.0MSoftware development
Jan 9N/AInternet services
Jan 9€15.0MBusiness applications

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.